Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier

Area of Science:

• Hepatology
• Neonatology
• Genetics

Background:

• Crigler-Najjar type 1 syndrome (CN1) is a rare genetic disorder affecting bilirubin metabolism.
• The UGT1A1 gene mutation c.222C>A underlies CN1, leading to severe unconjugated hyperbilirubinemia.
• CN1 poses significant risks of neurological damage (kernicterus) and mortality if untreated.

Purpose of the Study:

• To describe the pathophysiology, treatment, and outcomes of CN1 in a cohort of 28 patients.
• To validate the unbound bilirubin (Bf) and bilirubin-albumin ratio (BT/A) as predictors of neurological risk.
• To evaluate the efficacy of custom phototherapy systems and liver transplantation in managing CN1.

Main Methods:

• Measurement of unbound bilirubin (Bf) and total bilirubin (BT) in patient sera.
• Calculation of the molar bilirubin-albumin ratio (BT/A) to assess neurological risk.
• Development and application of custom high-irradiance phototherapy systems, with light dose titrated to maintain BT/A below 1.0.
• Assessment of clinical outcomes, including kernicterus and liver fibrosis (Lf).

Main Results:

• Unbound bilirubin showed nonlinear relationships with BT and BT/A, with significant individual variations in bilirubin-albumin binding.
• Fourteen percent of neonates developed kernicterus; BT ≥ 30 mg/dL and BT/A ≥ 1.0 mol:mol were equally predictive of brain injury.
• Starting phototherapy after 13 days of age increased kernicterus risk 3.5-fold.
• Consistent phototherapy maintained safe bilirubin levels in childhood, but levels increased annually.
• Liver transplantation (n=17) normalized bilirubin levels and eliminated phototherapy dependence, though liver explants showed fibrosis.

Conclusions:

• CN1 remains a severe and potentially fatal disorder despite advances in management.
• Early and consistent phototherapy, guided by bilirubin-albumin ratio monitoring, is critical for preventing kernicterus.
• Liver transplantation offers a definitive treatment, normalizing bilirubin levels and resolving phototherapy dependence.